UCSD Partners with Cofactor Genomics to Improve Patient Outcomes in Metastatic Head and Neck Cancer

San Diego, California--(Newsfile Corp. - September 15, 2020) - Physicians at the University of California, San Diego (UCSD) School of Medicine and Cofactor Genomics, the company bridging the precision medicine gap, today announced a partnership aimed at improving a physician’s ability to predict tumor response to immunotherapy, specifically in recurrent and metastatic squamous cell carcinoma of the head and neck (RM-HNSCC). Guiding and prioritizing therapy selection is especially important given last year’s FDA approval of pembrolizumab as a first line treatment for RM-HNSCC. The partnership is championed by Ezra Cohen, MD, Chief of the Division of Hematology‐Oncology at the UCSD Moores Cancer Center, and leverages Cofactor’s recently-patented Predictive Immune Modeling technology. 

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• USCD and Cofactor partner to improve physician's ability to predict tumor response.
• Ezra Cohen, MD, Chief of the Division of Hematology-Oncology at the UCSD Moores Cancer Center is the Primary Investigator for the collaboration.
• The study will leverage Cofactor's Predictive Immune Modeling platform to analyze clinical specimens and outcomes data well-curated by UCSD.

Click image above to view full announcement.

About Cofactor Genomics

Cofactor Genomics is bridging the precision medicine gap by building diagnostic tools to match the right patient to the right treatment at the right time. Predicting patient response to therapy currently relies on isolated, single-analyte biomarkers that have failed to deliver accurate therapy response predictions, resulting in unnecessary healthcare costs, and most harmfully, negative outcomes for patients. Cofactor's products use Predictive Immune Modeling, which leverages RNA data and machine learning to combine biological signals, creating multidimensional biomarkers to deliver on the promise of precision medicine. Cofactor Genomics offers its full-service molecular, informatic, and database tools to make drug discovery, clinical trials and therapy selection more successful. Find out more about how Cofactor Genomics is revolutionizing precision medicine at cofactorgenomics.com.

About UCSD

UC San Diego Health, comprising a comprehensive health system throughout San Diego County, UC San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, is one of five academic medical systems within the University of California system. We are committed to improving patient care while also researching new treatments and training tomorrow's doctors and pharmacists. For more than 50 years, our renowned clinicians and scientists have made advances in numerous fields, including minimally invasive surgeries, personalized cancer therapy, cardiovascular treatment and surgery, transplantation and the early detection of autism. Our specialty patient care is consistently ranked among the nation's best by U.S. News & World Report.

Contacts:

Mariesa Kemble, Chronic Communications Inc.
(608) 850-4745
kemblem@aol.com

Scott LaFee
(858) 249-0456
slafee@health.ucsd.edu

Heather Buschman, PhD
(858) 249-0456
hbuschman@health.ucsd.edu

Source: Cofactor Genomics

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/63860